BSD Medical Announces that Dr. Rüdiger Wessalowski has been Awarded the ESHO-BSD Award 2013 for his Pioneering Work in Hyperthermia Research

Business Wire

SALT LAKE CITY--(BUSINESS WIRE)--

BSD Medical Corporation (BSDM) (the “Company” or “BSD”) announced today that the ESHO-BSD Award for 2013 was awarded to Dr. Rüdiger Wessalowski in recognition of his pioneering work in the field of hyperthermia research. The award was presented at the annual meeting of the European Society for Hyperthermic Oncology (ESHO), which was held in Munich, June 19 to 22, 2013. Dr. Wessalowski is an Associate Professor at the renowned Paediatric Oncology Clinic, Haematology and Immunology, Centre for Child and Adolescent Health, Heinrich-Heine University, Dusseldorf, Germany. Dr. Wessalowski led the multidisciplinary research team from the authoritative MAKEI study group that conducted the seminal study on the addition of hyperthermia to chemotherapy to treat children and adolescents with recurrent germ cell tumors.

The study, which was published in the prestigious The Lancet Oncology, demonstrated significantly improved survival from the addition of hyperthermia to chemotherapy. (Rüdiger Wessalowski et al.; The Lancet Oncology, Early Online Publication, July 1, 2013, doi: 10.1016/S1470-2045[13]70271-7.) As part of this study, the research team established a treatment protocol that would allow clinicians to provide a long-term cure for most of these patients who have a very poor prognosis. The published study demonstrated an objective tumor reduction in 86% of the patients, with a 5-year overall survival rate of 72%, which is unmatched by any other clinical report on recurrent childhood malignant germ-cell tumors. This study also showed that hyperthermia activated chemotherapy drugs that had previously failed these patients.

"Dr. Wessalowski deserves appreciation and recognition for his remarkable achievements that have benefited society," said Harold Wolcott, BSD President. "His emphasis on making hyperthermia treatment for children and adolescents a quantifiable therapy will significantly influence how hyperthermia will be practiced in the future."

Dr. Wessalowski studied medicine in Dusseldorf and is the senior physician at the Paediatric Oncology Clinic, Haematology and Immunology, Centre for Child and Adolescent Health, Heinrich-Heine University, Dusseldorf, German. Dr. Wessalowski is focused on clinical research into new treatments using hyperthermia for the treatment of children and adolescents suffering from malignant tumors that have relapsed or not responded to standard therapies.

About ESHO and the ESHO-BSD Award

The aim of the European Society for Hyperthermic Oncology (ESHO) is the promotion of research in physics, engineering, biology and medicine to clinical application of hyperthermia in cancer therapy. This professional society was founded in England in 1987 and currently has its headquarters in Rotterdam, Netherlands. The ESHO-BSD Award is presented yearly to one of the members of ESHO who has made valuable contributions to the field of hyperthermia. The beneficiary of the award is determined each year by a select group of former award recipients.

About the BSD-2000 Hyperthermia System

The BSD-2000 – developed and patented exclusively by BSD – delivers localized therapeutic heating (hyperthermia) by applying radiofrequency (RF) energy. The BSD-2000 creates a central focusing of energy that can be electronically focused to target the shape, size and location of the tumor, thus providing dynamic control of the heating delivered to the tumor region. The BSD-2000 has Humanitarian Device Exemption (HDE) marketing approval from the U.S. Food and Drug Administration (FDA) for use in conjunction with radiation therapy for the treatment of cervical cancer patients who are ineligible for chemotherapy. The BSD-2000 also has CE (Conformité Européenne) Marking approval for the commercial sale in Europe. CE Marking approval is also recognized in many countries outside of the EU.

About BSD Medical Corporation

BSD Medical Corporation develops, manufactures, markets and services systems to treat cancer and benign diseases using heat therapy delivered using focused radiofrequency (RF) and microwave energy. BSD’s product lines include both hyperthermia and ablation treatment systems. BSD’s hyperthermia cancer treatment systems, which have been in use for several years in the United States, Europe and Asia, are used to treat certain tumors with heat (hyperthermia) while increasing the effectiveness of other therapies such as radiation therapy. BSD’s microwave ablation system has been developed as a stand-alone therapy to employ precision-guided microwave energy to ablate (destroy) soft tissue. The Company has developed extensive intellectual property, multiple products in the market and established distribution in the United States, Europe and Asia. Certain of the Company’s products have received regulatory approvals and clearances in the United States, Europe and China. For further information visit BSD Medical's website at www.BSDMedical.com.

This press release may be deemed to contain forward-looking statements, which are subject to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including the expected use of proceeds relating to the recently completed offering. Readers are cautioned that these forward-looking statements are only predictions and may differ materially from actual future events or results due to a variety of factors, including, among other things, the demand for the Company’s products, the ability of the Company to produce the products to meet the demand, global economic conditions and uncertainties in the geopolitical environment and other risk factors set forth in the Company’s most recent reports on Form 10-K and Form 10-Q. Any forward-looking statements in this release are based on limited information currently available to the Company, which is subject to change, and the Company will not necessarily update the information.

Contact:
BSD Medical Corporation
William (Bill) S. Barth, 801-972-5555
Facsimile: 801-972-5930
investor@bsdmc.com
View Comments